There are currently 1119 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181
Recruiting
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/18/2025
Locations: Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio +4 locations
Conditions: Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor, Malignant Ovarian Teratoma, Stage I Ovarian Choriocarcinoma, Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage I Ovarian Teratoma AJCC v6 and v7, Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage I Testicular Choriocarcinoma AJCC v6 and v7, Stage I Testicular Embryonal Carcinoma AJCC v6 and v7, Stage I Testicular Yolk Sac Tumor AJCC v6 and v7, Stage II Ovarian Choriocarcinoma, Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage II Testicular Choriocarcinoma AJCC v6 and v7, Stage II Testicular Embryonal Carcinoma AJCC v6 and v7, Stage II Testicular Yolk Sac Tumor AJCC v6 and v7, Stage III Ovarian Choriocarcinoma, Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage III Testicular Choriocarcinoma AJCC v6 and v7, Stage III Testicular Embryonal Carcinoma AJCC v6 and v7, Stage III Testicular Yolk Sac Tumor AJCC v6 and v7, Stage IV Ovarian Choriocarcinoma, Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Teratoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor, Stage I Testicular Seminoma AJCC v6 and v7
Register for Updates
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741
Recruiting
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/18/2025
Locations: UC Health Holmes, Cincinnati, Ohio
Conditions: Cystic Fibrosis
Register for Updates
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: University of Cincinnati-COM, Cincinnati, Ohio
Conditions: Severe Hypertriglyceridemia
Register for Updates
The DISCOVER INOCA Prospective Multi-center Registry
NCT05288361
Recruiting
The overall objective of this multi-center registry is to identify specific phenotypes of INOCA with both an anatomic evaluation (coronary angiography and intravascular imaging) and physiologic assessment with the Abbott Coroventis Coroflow Cardiovascular System, and to determine long-term outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: The Christ Hospital, Cincinnati, Ohio
Conditions: Ischemia and no Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Coronary Vasospasm, Endothelial Dysfunction, Microvascular Angina, Chest Pain With Normal Coronary Angiography
Register for Updates
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
NCT03115333
Recruiting
This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient?s response to treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio
Conditions: Gliosarcoma, Recurrent Glioblastoma
Register for Updates
Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years with ADHD
NCT06431256
Recruiting
This study will evaluate the efficacy, safety and pharmacokinetics of HLD200 (20 mg and 40 mg) in children aged 4 to 5 years with ADHD.
Gender:
ALL
Ages:
Between 4 years and 5 years
Trial Updated:
03/14/2025
Locations: University of Cincinnati Health, Cincinnati, Ohio
Conditions: Attention Deficit Hyperactivity Disorder
Register for Updates
Social & Contextual Impact on Children Undergoing Liver Transplantation
NCT04551742
Recruiting
The social determinants of health have a large impact on health. For example, neighborhood socioeconomic deprivation is associated with increased risk of medication non-adherence, graft failure, and death in children after liver transplant. In order to address these socioeconomic inequities in outcomes, a more granular understanding of how the social determinants of health impact outcomes is needed. In this observational prospective cohort, caregivers of children undergoing liver transplantation... Read More
Gender:
ALL
Ages:
70 years and below
Trial Updated:
03/13/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Liver Transplantation, Liver Diseases
Register for Updates
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
NCT05271409
Recruiting
The main objective of the study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/13/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Register for Updates
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio +4 locations
Conditions: Previously Treated Non-Small Cell Lung Cancer
Register for Updates
A Clinical Study to Evaluate DNTH103 in Adults with Multifocal Motor Neuropathy
NCT06537999
Recruiting
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with multifocal motor neuropathy (MMN).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/12/2025
Locations: Clinical Study Site, Cincinnati, Ohio
Conditions: Multifocal Motor Neuropathy
Register for Updates
JUPITER 4.0 - Risk Factors for Failure of Isolated Medial Patellofemoral Ligament Reconstruction
NCT06883396
Recruiting
The goal of this observational study is to learn about the outcomes of medial patellofemoral ligament (MPFL) reconstruction for the treatment of recurrent patellar instability. The main questions it aims to answer are: * What are the risk factors for recurrent patellar instability after MPFL reconstruction? * What functional outcomes do patients report after MPFL reconstruction? Participants undergoing MPFL reconstruction will answer survey questions about their knee and activity level 1 year... Read More
Gender:
ALL
Ages:
Between 10 years and 35 years
Trial Updated:
03/12/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Patellar Dislocation, Recurrent, Patellar Dislocation, Patellar Instability, Patellofemoral Dislocation, Patellofemoral Joint Dislocation, Patellofemoral Disorder
Register for Updates
A Study of DB-OTO, an Adeno-associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations
NCT05788536
Recruiting
Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat children who have hearing loss due to changes in the otoferlin gene. The purpose of this study is to: * Learn about the safety of DB-OTO * Determine how well DB-OTO is tolerated (does not cause ongoing discomfort) * Evaluate the efficacy of DB-OTO (how well DB-OTO works)
Gender:
ALL
Ages:
17 years and below
Trial Updated:
03/12/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Register for Updates